Literature DB >> 10706061

Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model.

C Yu1, P Linsley, K Seidel, G Sale, H J Deeg, R A Nash, R Storb.   

Abstract

BACKGROUND: We studied whether blocking of the T cell costimulatory signal from B7-->CD28 by cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein would, either by itself or when added to methotrexate/cyclosporine, result in improved graft-versus-host disease prevention after dog leukocyte antigen nonidentical canine hematopoietic stem cell transplantation after 920 cGy total body irradiation. RESULTS AND
CONCLUSIONS: Survivals of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein-treated dogs were only slightly prolonged over controls. It appeared that the addition of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein failed to induce graft-host tolerance in this model beyond that achieved with methotrexate/cyclosporine alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706061     DOI: 10.1097/00007890-200002150-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

Review 1.  Allogeneic hematopoietic cell transplantation: the state of the art.

Authors:  Boglarka Gyurkocza; Andrew Rezvani; Rainer F Storb
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

Review 2.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

3.  Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig.

Authors:  Scott S Graves; Diane Stone; Carol Loretz; Laura Peterson; Jeannine S McCune; Marco Mielcarek; Rainer Storb
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

4.  GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.

Authors:  Weston P Miller; Swetha Srinivasan; Angela Panoskaltsis-Mortari; Karnail Singh; Sharon Sen; Kelly Hamby; Taylor Deane; Linda Stempora; Jonathan Beus; Alexa Turner; Caleb Wheeler; Daniel C Anderson; Prachi Sharma; Anapatricia Garcia; Elizabeth Strobert; Eric Elder; Ian Crocker; Timothy Crenshaw; M Cecilia T Penedo; Thea Ward; Mingqing Song; John Horan; Christian P Larsen; Bruce R Blazar; Leslie S Kean
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

Review 5.  Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old.

Authors:  L S Kean; K Singh; B R Blazar; C P Larsen
Journal:  Am J Transplant       Date:  2011-12-17       Impact factor: 8.086

Review 6.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

7.  Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.

Authors:  M Lupu; R Storb
Journal:  Vet Comp Oncol       Date:  2007-03       Impact factor: 2.613

8.  Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Scott S Graves; Maura H Parker; Rainer Storb
Journal:  ILAR J       Date:  2018-12-31

Review 9.  Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.

Authors:  Gérard Socié; Leslie S Kean; Robert Zeiser; Bruce R Blazar
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 19.456

Review 10.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.